First‐line immune checkpoint therapy in metastatic squamous cell lung cancer harboring both EGFR mutation and high expression of PD‐L1: A case report

A 90‐year‐old female was admitted to our hospital with a history of a dry cough. Chest computed tomography (CT) scan showed a tumor shadow, and CT‐guided lung biopsy revealed squamous cell carcinoma harboring an EGFR mutation. In addition, programmed death‐ligand 1 (PD‐L1) was highly expressed with a tumor proportion score (TPS) of >75%. Pembrolizumab therapy in the first‐line setting was not effective, and the patient died at six months from the first visit. Squamous cell lung cancers (SCLCs) with both EGFR mutation and high expression of PD‐L1 are very rare.

[1]  J. Goldman,et al.  A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor (TKI) naïve patients with advanced NSCLC. , 2018 .

[2]  Y. Oda,et al.  PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements. , 2018, Lung cancer.

[3]  J. Horton,et al.  A Phase II Study of Pembrolizumab in EGFR‐Mutant, PD‐L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  B. Cho,et al.  Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer. , 2017, Lung cancer.

[5]  Jingqi Zhuang,et al.  Efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in targeted therapy of lung squamous cell carcinoma patients with EGFR mutation: a pooled analysis , 2017, Oncotarget.

[6]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[7]  T. Nakajima,et al.  Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody , 2016, Investigational New Drugs.

[8]  S. Digumarthy,et al.  EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis , 2016, Clinical Cancer Research.

[9]  K. Goto,et al.  A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC). , 2013, Lung cancer.

[10]  Jeremy J. W. Chen,et al.  High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients. , 2019, Lung cancer.